MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

Home・Akcijų sąrašas・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.63 1.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.55

Max

1.63

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.8M -16M
Pardavimai	-8.7M 5.5M
Pelno marža	-282.723
Darbuotojai	81
EBITDA	-4.2M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+140.88% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-12M 640M
Ankstesnė atidarymo kaina	-0.24
Ankstesnė uždarymo kaina	1.63

Naujienos nuotaikos

By Acuity

94%

3 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

0.6863 / 0.72 Palaikymas ir pasipriešinimas

Lexicon Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-06 23:17; UTC

Uždarbis

Samsung Forecasts Record First-Quarter Operating Profit

2026-04-06 23:00; UTC

Karštos akcijos

Stocks to Watch: Health Insurers, Mawson, Owlet

2026-04-06 22:13; UTC

Pagrindinės rinkos jėgos

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026-04-06 21:46; UTC

Įsigijimai, susijungimai, perėmimai

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-04-06 16:56; UTC

Svarbiausios naujienos

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026-04-06 14:47; UTC

Pagrindinės rinkos jėgos

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026-04-07 00:00; UTC

Svarbiausios naujienos

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026-04-06 23:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026-04-06 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026-04-06 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026-04-06 23:15; UTC

Rinkos pokalbiai

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026-04-06 22:14; UTC

Rinkos pokalbiai

Correction to Live Cattle Futures Article

2026-04-06 20:56; UTC

Rinkos pokalbiai

Mexican Private Consumption Fell in January -- Market Talk

2026-04-06 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-06 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026-04-06 19:11; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026-04-06 19:06; UTC

Rinkos pokalbiai

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026-04-06 18:36; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 17:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026-04-06 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 16:33; UTC

Rinkos pokalbiai

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026-04-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-06 14:59; UTC

Uždarbis

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Akcijų palyginimas

Kainos pokytis

Lexicon Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

140.88% į viršų

12 mėnesių prognozė

Vidutinis 3.83 USD 140.88%

Aukščiausias 6 USD

Žemiausias 1 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Lexicon Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Lexicon Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.6863 / 0.72Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Rinkos nuotaikos

By Acuity

3 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.